{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T16:44:23Z","timestamp":1765212263278,"version":"3.46.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,8]]},"DOI":"10.7759\/cureus.98725","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T16:40:16Z","timestamp":1765212016000},"source":"Crossref","is-referenced-by-count":0,"title":["Pembrolizumab-Induced Choriocapillaritis and Orbital Inflammation: A Case Report"],"prefix":"10.7759","author":[{"given":"Oumaima","family":"El Korno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zineb","family":"Hilali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taha","family":"Boutaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassna","family":"El Ghazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saad","family":"Benchekroun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samira","family":"Tachfouti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdellah","family":"Amazouzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lalla Ouafa","family":"Cherkaoui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas A","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018, 359:1350-55. 10.1126\/science.aar4060","journal-title":"Science"},{"key":"ref2","article-title":"Pembrolizumab","author":"Flynn JP","year":"2025","unstructured":"Flynn JP, Gerriets V. Pembrolizumab. StatPearls [Internet], Treasure Island (FL): StatPearls Publishing; 2025."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11174993","article-title":"Ocular inflammation induced by immune checkpoint inhibitors","volume":"11","author":"Chaudot F","year":"2022","unstructured":"Chaudot F, S\u00e8ve P, Rousseau A, et al.. Ocular inflammation induced by immune checkpoint inhibitors. J Clin Med. 2022, 11:10.3390\/jcm11174993","journal-title":"J Clin Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s12348-022-00321-2","article-title":"Ocular adverse events associated with immune checkpoint inhibitors, a scoping review","volume":"13","author":"Martens A","year":"2023","unstructured":"Martens A, Schauwvlieghe PP, Madoe A, Casteels I, Aspeslagh S. Ocular adverse events associated with immune checkpoint inhibitors, a scoping review. J Ophthalmic Inflamm Infect. 2023, 13:5. 10.1186\/s12348-022-00321-2","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12112547","article-title":"Emerging ocular side effects of immune checkpoint inhibitors: a comprehensive review","volume":"12","author":"Wu KY","year":"2024","unstructured":"Wu KY, Yakobi Y, Gueorguieva DD, Mazerolle \u00c9. Emerging ocular side effects of immune checkpoint inhibitors: a comprehensive review. Biomedicines. 2024, 12:10.3390\/biomedicines12112547","journal-title":"Biomedicines"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/reports8030154","article-title":"Immune checkpoint inhibitor-induced ocular toxicity: a case of pembrolizumab-associated corneal ulceration and evisceration","volume":"8","author":"Caldarelli M","year":"2025","unstructured":"Caldarelli M, Brisinda D, De Matteis G, De Vito F, Gambini G, Cianci R, Gambassi G.  Immune checkpoint inhibitor-induced ocular toxicity: a case of pembrolizumab-associated corneal ulceration and evisceration. Reports (MDPI). 2025, 8:10.3390\/reports8030154","journal-title":"Reports (MDPI)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2018.1851","article-title":"Birdshot-like chorioretinopathy associated with pembrolizumab treatment","volume":"136","author":"Acaba-Berrocal LA","year":"2018","unstructured":"Acaba-Berrocal LA, Lucio-Alvarez JA, Mashayekhi A, Ho AC, Dunn JP, Shields CL. Birdshot-like chorioretinopathy associated with pembrolizumab treatment. JAMA Ophthalmol. 2018, 136:1205-207. 10.1001\/jamaophthalmol.2018.1851","journal-title":"JAMA Ophthalmol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2021.101072","article-title":"A case of panuveitis and retinal vasculitis associated with pembrolizumab therapy for metastatic lung cancer","volume":"22","author":"Kim KW","year":"2021","unstructured":"Kim KW, Kusuhara S, Tachihara M, Mimura C, Matsumiya W, Nakamura M. A case of panuveitis and retinal vasculitis associated with pembrolizumab therapy for metastatic lung cancer. Am J Ophthalmol Case Rep. 2021, 22:101072. 10.1016\/j.ajoc.2021.101072","journal-title":"Am J Ophthalmol Case Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1171981","article-title":"Pembrolizumab-induced optic neuropathy-a case report","volume":"14","author":"Daetwyler E","year":"2023","unstructured":"Daetwyler E, Zippelius A, Meyer P, L\u00e4ubli H. Pembrolizumab-induced optic neuropathy-a case report. Front Immunol. 2023, 14:1171981. 10.3389\/fimmu.2023.1171981","journal-title":"Front Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2019.1577978","article-title":"Uveitis in patients treated with CTLA-4 and PD-1 checkpoint blockade inhibition","volume":"28","author":"Sun MM","year":"2020","unstructured":"Sun MM, Levinson RD, Filipowicz A, et al.. Uveitis in patients treated with CTLA-4 and PD-1 checkpoint blockade inhibition. Ocul Immunol Inflamm. 2020, 28:217-27. 10.1080\/09273948.2019.1577978","journal-title":"Ocul Immunol Inflamm"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider BJ","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021, 39:4073-126. 10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14030336","article-title":"iagnosing and managing uveitis associated with immune checkpoint inhibitors: a review","volume":"14","author":"Zhang H","year":"2024","unstructured":"Zhang H, Houadj L, Wu KY, Tran SD. iagnosing and managing uveitis associated with immune checkpoint inhibitors: a review. Diagnostics (Basel). 2024, 14:336. 10.3390\/diagnostics14030336","journal-title":"Diagnostics (Basel)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/442199-pembrolizumab-induced-choriocapillaritis-and-orbital-inflammation-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T16:40:16Z","timestamp":1765212016000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/442199-pembrolizumab-induced-choriocapillaritis-and-orbital-inflammation-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.98725","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,8]]}}}